First patient dosed in Phase 1 trial testing AML T-cell treatment
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid…
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid…
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…
A European regulatory committee has recommended approval of a fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) for adults with previously untreated chronic lymphocytic leukemia…
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia (AML), an aggressive type of…
April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML) and raise funds for research…
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…